Compare KraneShares CSI China Internet ETF (KWEB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Novartis AG — how do they compare? KraneShares CSI China Internet ETF trades at $24.9 (market cap $4.37B), while Novartis AG trades at $143.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 61.5× KraneShares CSI China Internet ETF's market cap, and Novartis AG pays a 3.31% dividend while KraneShares CSI China Internet ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Novartis AG for 82 Days on average.
| KWEB | NVS | |
|---|---|---|
Market Cap | $4.37B | $268.57B |
Volume | 13,393,361 | 1,532,573 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $168.62 |
52-Week Low | $23.63 | $121.80 |
Typical Hold Time | 57 Days | 82 Days |
Enterprise Value | — | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $24.87, up 2.22% over the past 24 hours. Technical indicators show a bearish trend with moving averages signaling sell, while oscillators are neutral. Recent news highlights institutional activity, including a stake reduction by Tidal Investments LLC and an increase by HSBC Holdings PLC, amid ongoing U.S.-China trade dynamics and economic data releases.
The outlook for KWEB is clouded by geopolitical tensions and economic headwinds in China, though corporate profit growth offers a potential catalyst. Key risks include trade policy shifts and weak domestic consumption. Investors should weigh institutional movements against broader market sentiment for balanced exposure.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
